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1. Introduction
   The recent outbreak of Ebola virus (EBOV) infection in 
Africa affects many countries, such as Guinea, Liberia, 
Sierra Leone, Nigeria, Senegal and Democratic Republic 
of the Congo and has not ceased. It is considered as the 
largest outbreak of EBOV disease ever recorded and is 
presently having devastating effects in West Africa. So far, 
this has already resulted in the deaths of >3 132 individuals 
associated with >6 643 recorded cases, with a mortality 
rate of approximately 51%[1,2], and there are estimates of 
occurrence of >20 000 cases in the next nine months[3].
   EBOV is a highly pathogenic virus that has caused an 
increasing number of outbreaks in central Africa in the past 
decade and currently in West Africa. Due to its high fatality 
rate, it is very important to understand the mechanisms of 
pathogenesis and transmission to run an effective control 
and surveillance and to develop appropriate vaccines and 
therapeutics[4].
   Ebola is Filoviridae, composed of a small group of non-
segmented negative-strand RNA viruses, belonging to the 
order Mononegavirales. Filoviridae consists of one genus, 
filovirus, which contains two species: Ebola virus and 
Marburg virus, morphologically identical but serologically 
different[5].
   EBOV hemorrhagic fever is a zoonotic disease that can 
be transmitted accidentally by direct contact with infected 
live or dead animals. Several researchers have attempted to 
unravel the natural history of EBOV in Africa since the first 
recorded human outbreak in 1976, along the Ebola River 
in Democratic Republic of Congo and Sudan. This can be 
defined as different ways in which this virus circulates in 
its natural environment, from its natural host to susceptible 
intermediate animal species (which worsen fatal infection), 
and then to humans, either via the natural host or through 
intermediate species (Figure 1)[6-8].






The current outbreak of Ebola virus in West Africa has become a devastating problem, with a 
mortality rate around 51%; over 3 132 deaths have been confirmed and even more are expected in 
this case. The virus causes a characteristic disease known as hemorrhagic fever. Its symptoms 
range from nonspecific signs such as fever, to more specific problems such as serious bleeding. 
Transmission occurs easily when a person comes in contact with contaminated fluids. Treatment 
is supportive because there are still no specific drugs for use. The present review focuses on the 
main features related to the Ebola virus, its transmission, pathogenesis, treatment and control 
forms. There is little in-depth knowledge about this disease, but its severity requires attention 
and information to prevent a worse scenario than the current.
Article history:
Received 6 Oct 2014
Accepted 7 Oct 2014 
Available online 10 Oct 2014
 Contents lists available at ScienceDirect
Zulane Lima Sousa/Asian Pac J Trop Biomed 2014; 4(11): 842
Natural host(s) 
(Bats,others?)
Susceptible intermediate animal species 
(gorillas, chimpanzees, duikers)




Figure 1. Natural history of Ebola virus.
2. Transmission
   About the mechanisms of Ebola virus transmission in 
nature, it is known that once humans become infected, 
subsequent EBOV transmission continue to occur person-
to-person mainly as a result of close contact with 
secretions, blood or tissues from patients. But how Ebola 
virus is originally passed to humans, nonhuman primates 
and/or other susceptible animal species, and what other 
factors might be involved in this transmission remains 
unclear yet[7].
   Some animal species, as great apes and apparently 
duiker, are naturally infected by the virus, probably directly 
from a natural reservoir. These intermediate animal species 
develop a disease, which is often fatal. These infected 
animals thus spread the virus to other ecological niches 
linked to their environment and behaviors. After the death, 
their carcasses remain infectious for humans, who transmit 
the disease through community. Identification of the natural 
life cycle and determination of the virus reservoir should 
help in the development of strategies for preventing or 
controlling human outbreaks[8].
   It is possible that humans can be directly infected 
by (unknown) EBOV reservoir species. Fruit bats of the 
Pteropodidae family are considered as the natural host 
of the Ebola virus. Bats seem to be involved with the 
first people to be infected during the 1976 and 1979 
outbreaking in Nzara, Sudan. No other likely source of 
infection was identified in either outbreak. Added to this 
fact, an Australian who was infected by Marburg virus in 
Johannesburg, in 1975, had just returned from a trip to 
Zimbabwe, during which attended a site inhabited by many 
bats[8,9].
   Ebola is not airborne, nor foodborne or waterborne. The 
initial human-to-human transmission must occur through 
contact with the body fluids of an infected patient. The 
EBOV does not infect other individuals during the the period 
between the initial infection and the onset of symptoms 
(incubation period), which can be 2-21 d[9].
   It is believed that Ebola virus infection is transmitted 
through contact with body fluids or blood from infected 
monkeys or patients. Similarly certain family members 
became infected when caring for Ebola patients. How the 
infection enters the body remains unclear. The most likely 
route of infection is through contact of contaminated fingers 
with the conjunctiva or oral mucosa. Another characteristic 
is that the virus also can persist in convalescent patients. 
The finding of EBOV in body fluids of convalescent 
patients suggests that transmission may occur even during 
convalescence. But it is not clear how such patients can 
contribute to transmission[10,11].
   Through the study in the families of 34 cases in Nzara in 
1979, airborne transmission seems unlikely, showing the 
absence of risk due to simple cohabitation in the same 
room[5]. But transmission through aerosolized particles or 
vomit cannot be excluded completely, though it is believed 
that the major mode of transmission is through direct 
contact[11]. Because aerial transmission is of concern in 
the case of filovirus infections, the possibility of airborne 
transmission via animal-to-human and human-to-human 
transmission still needs to be known[12].
   Due to the systemic nature of the infection in humans, it 
seems likely that a mammalian reservoir host is infected 
not only across the surface of the body, but also through 
the mucous membranes of the respiratory and intestinal 
tracts, for then a hematogenous spread occur along with 
subsequent infection of the tissues and organs and finally 
bleeding[13].
3. Pathogenesis
   The key events that lead to shock and death are the 
impaired protective immunological responses, disseminated 
intravascular coagulation and increase in vascular 
permeability[6]. The model for EBOV pathogenesis is that, 
after entering the host, EBOV targets macrophages and 
dendritic cells, inducing an inflammatory state with high 
levels of proinflammatory cytokines. Simultaneously, the 
virus evades an immune response by some mechanisms 
including depletion of natural killer cells and lymphocytes 
and impairment of dendritic cells function. With infection 
of macrophages, they become activated and produce 
proinflammatory cytokines and tissue factor, thus provoking 
a pro-coagulant state. This state impairs endothelial barrier 
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function and develops into disseminated intravascular 
coagulation. Together, these events can lead to severe shock 
and death[4].
   Virus induced shock has been associated with abnormal 
production of nitric oxide which is related to the loss 
of vascular integrity[14]. Shock syndrome can also have 
a contribution of platelet-derived agents triggered by 
damaged endothelial cells. Thus, gross damage of other 
organs can inducing thrombi formation in multiple organs 
and also cause disseminated intravascular coagulation in 
multiple organs[15].
4. Clinical features
   After an incubation period that ranges from 2 to 21 d, 
infected individuals appear fever, chills, and malaise. An 
often early clinical sign is a conjunctival infection. Then 
occurs symptoms such as anorexia, vomiting, prostration, 
chest pain, and shortness of breath develop. A valuable 
differential diagnostic feature that may occur is the 
maculopapular rash related with erythema. In the prime 
of the disease, vascular dysfunction occurs as petechiae, 
ecchymoses, melena, menorrhagia, bleeding at needle 
puncture sites, presence of blood in the urine or faeces, 
mucosal bleeding and diffuse coagulopathy[4,6,11].
   Between Day 6 and 16 may develop shock, multiorgan 
failure and coma with death due to vascular dysfunction[6]. 
Death is preceded by the appearance of hypotension, 
tachypnea, tachycardia and anuria [5].  A common 
consequence of infection is abortion, and newborns 
of mothers who die of infection are fatally infected. 
Convalescence is slow and marked by weight loss and 
prostration[13].
5. Diagnosis 
   The suspicion of Ebola hemorrhagic fever is based 
on clinical manifestations and on a history of contact 
with an infected person[11]. Laboratory diagnosis can be 
performed based on the detection of virus particles, particle 
components or virus specific antibodies[6]. But a method 
of practical and safe diagnosis would be helpful in Ebola 
outbreaks. In 1995, a diagnosis of Ebola hemorrhagic 
fever was difficult to confirm patient diagnosis in Kikwit, 
Democratic Republic of the Congo, due to lack of a safe and 
simple-to-use field diagnostic test[16].
6. Treatment 
   Currently, the treatment of Ebola hemorrhagic fever is no 
specific, but is mainly symptomatic and supportive. The 
proper intensive care treatment should be directed towards 
pain reduction, maintenance of electrolyte balance and 
effective blood volume[6,11,14].
   Despite the absence of any specific antiviral drugs for the 
treatment of disease, inhibiting overexpression of tissue 
factor has been considered as a therapeutic approach, due to 
it has a profound effect in the development of disseminated 
intravascular coagulation[4].
   Some drug candidates for treatment of Ebola hemorrhagic 
fever, such as estrogen receptor modulators, interferon, 
neutralizing monoclonal antibodies, rNAPc2 or siRNA, when 
administered shortly after infection, has shown protection, 
but do not have a therapeutic benefit after 2 d post infection. 
Another drug, pyrazinecarboxamide derivative T-705 
(favipiravir), has demonstrated effectiveness against EBOV in 
vitro and in vivo (in mice), which makes it a promising drug 
candidate for treatment of Ebola hemorrhagic fever. But 
human clinical trials are still needed. This demonstrates that 
the investment in research to develop an effective antiviral 
therapy for human use is still necessary in this case[17].
7. Control and prevention
   The control of Ebola virus infection has been further 
complicated due to the rapid progression of this disease. 
Decontamination plays an important role in preventing the 
spread of this infection because it is highly contagious[18, 
19]. Some control actions are recommended, such as early 
diagnosis with patient isolation, barrier nursing procedures, 
use of personal protective equipment by doctors, nurses, and 
caretakers, adherence to biosafety guidelines in laboratories 
and disinfection of contaminated areas and objects, and safe 
burials[14,20].
   For the prevention of outbreaks of Ebola hemorrhagic 
fever, local people should avoid contacting with potential 
virus hosts such as bats, great apes or other susceptible 
animal species because evidence suggests that human 
filovirus infection directly come from these animals[7].
8. Conclusion
   Currently, strict quarantine and symptomatic therapy are 
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considered suitable to prevent transmission of EBOV disease. 
But it can be seen that this is not enough, since the outbreak 
in West Africa has persisted and amplified over the past ten 
months. This can be because the outbreak spread to other 
countries, and inadequate medical system and traditional 
funeral proceedings in Africa that mourners often physically 
touch the body of the deceased[9].
   The main obstacles in reducing the virus transmission is 
lack of knowledge and potential panic over the disease. The 
local residents of Sadialu village in Sierra Leone, which were 
infected with EBOV, refused to be hospitalized. There were 
rumours saying that the interventions to administer patients 
actually caused the disease[21].
   The population of West Africa which includes people 
living in poor conditions and below the poverty line, turns 
out to be very susceptible to infection by EBOV. Such 
population is often overlooked by government and depends 
on the action of many volunteers who are willing to help 
them. This current outbreak of EBOV makes the precarious 
situation of inhabitants in West Africa  more visible, waiting 
for an effective help for restoring and maintaining their 
health.
  
Conflict of interest statement
    I declare that I have no conflict of interest.
References
[1]    Bausch DG, Bangura J, Garry RF, Goba A, Grant DS, Jacquerioz 
FA, et al. A tribute to Sheik Humarr Khan and all the healthcare 
workers in West Africa who have sacrificed in the fight against 
Ebola virus disease: Mae we hush. Antiviral Res 2014; 111C: 33-
35.
[2]    World Health Organization. WHO: Ebola response roadmap 
update. Geneva: World Health Organization; 2014. [Online] 
Available from: http://apps.who.int/iris/bitstream/10665/135029/1/
roadmapupdate26sept14_eng.pdf?ua=1 [Accessed on 27th 
September, 2014]
[3]    Ansari AA. Clinical features and pathobiology of Ebolavirus 
infection. J Autoimmun 2014; doi: 10.1016/j.jaut.2014.09.001. 
[4]    Hoenen T, Groseth A, Falzarano D, Feldmann H. Ebola virus: 
unravelling pathogenesis to combat a deadly disease. Trends 
Mol Med 2006; 12: 206-215.
[5]    Le Guenno B, Galabru J. Ebola virus. Bull Inst Pasteur 1997; 95: 
73-83.
[6]    Brown KS, Silaghi A, Feldmann H. Ebola virus. In: Mahy BWJ, 
van Regenmortel MHV, editors. Encyclopedia of virology. 3rd 
ed. Vol 2. Oxford: Elsevier; 2008, p. 57-65.
[7]    Groseth A, Feldmann H, Strong JE. The ecology of Ebola virus. 
Trends Microbiol 2007; 15: 408-416.
[8]    Pourrut X, Kumulungui B, Wittmann T, Moussavou G, Délicat 
A, Yaba P, et al. The natural history of Ebola virus in Africa. 
Microbes Infect 2005; 7: 1005-1014.
[9]    Ki  M.  What  do we real ly  fear? The epidemiological 
characteristics of Ebola and our preparedness. Epidemiol 
Health 2014; doi: 10.4178/epih/e2014014. eCollection 2014.
[10]  Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, 
Sanchez A, et al. Assessment of the Risk of Ebola Virus 
Transmission from Bodily Fluids and Fomites. J Infect Dis 2007; 
196(Suppl 2): S142-S147.
[11]  Colebunders R, Borchert M. Ebola hemorrhagic fever-a review. 
J Infect 2000; 40: 16-20.
[12]  Feldmann H, Wahl-Jensen V, Jones SM, Ströher U. Ebola virus 
ecology: a continuing mystery. Trends Microbiol 2004; 12: 433-
437.
[13]  Murphy FA, Peters CJ. Ebola virus: where does it come from and 
where is it going? In: Krause RM, editor. Emerging infections. 
New York: Academic Press; 1998, p. 375-410.
[14]  Feldmann H, Geisbert TW. Ebola hemorrhagic fever. Lancet 
2011; 377: 849-862.
[15]  Takada A, Kawaoka Y. The pathogenesis of Ebola hemorrhagic 
fever. Trends Microbiol 2001; 9: 506-511.
[16]  Heymann DL, Barakamfitiye D, Szczeniowski M, Muyembe-
Tamfum JJ, Bele O, Rodier G. Ebola hemorrhagic fever: lessons 
from Kikwit, Democratic Republic of the Congo. J Infect Dis 
1999; 179(Suppl 1): S283-S286.
[17]  Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela 
C, Günther S. Successful treatment of advanced Ebola virus 
infection with T-705 (favipiravir) in a small animal model. 
Antiviral Res 2014; 105: 17-21.
[18]  Chepurnov AA, Bakulina LF, Dadaeva AA, Ustinova EN, 
Chepurnova TS, Baker JR Jr. Inactivation of Ebola virus with a 
surfactant nanoemulsion. Acta Trop 2003; 87: 315-320.
[19]  Sullivan N, Yang ZY, Nabel GJ. Ebola virus pathogenesis: 
implications for vaccines and therapies. J Virol 2003; 77: 9733-
9737.
[20]  Briand S, Bertherat E, Cox P, Formenty P, Kieny MP, Myhre JK, 
et al. The international Ebola emergency. N Engl J Med 2014; 
371: 1180-1183.
[21]  Tambo E, Ugwu EC, Ngogang JY. Need of surveillance response 
systems to combat Ebola outbreaks and other emerging 
infectious diseases in African countries. Infect Dis Poverty 2014; 
3: 29.
